|
US5248671A
(en)
|
1989-02-15 |
1993-09-28 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
|
US5087617A
(en)
|
1989-02-15 |
1992-02-11 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
|
US5602240A
(en)
*
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US6111094A
(en)
|
1990-08-14 |
2000-08-29 |
Isis Pharmaceuticals Inc. |
Enhanced antisense modulation of ICAM-1
|
|
US6015886A
(en)
*
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
AU683957B2
(en)
|
1993-11-05 |
1997-11-27 |
Amgen, Inc. |
Liposome preparation and material encapsulation method
|
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
|
US7309692B1
(en)
|
1996-07-08 |
2007-12-18 |
Board Of Regents, The University Of Texas System |
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US7262173B2
(en)
|
1997-03-21 |
2007-08-28 |
Georgetown University |
Chemosensitizing with liposomes containing oligonucleotides
|
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
|
US20030180789A1
(en)
*
|
1998-12-30 |
2003-09-25 |
Dale Roderic M.K. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
|
AU2197600A
(en)
|
1998-12-30 |
2000-07-24 |
Oligos Etc. Inc. |
Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
|
|
US7098192B2
(en)
*
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
WO2001026625A2
(en)
|
1999-10-08 |
2001-04-19 |
Alza Corp |
Neutral-cationic lipid for nucleic acid and drug delivery
|
|
US20050186264A1
(en)
|
2000-10-12 |
2005-08-25 |
Kiani Mohammad F. |
Targeting drug/gene carriers to irradiated tissue
|
|
AU2002241952A1
(en)
|
2001-01-22 |
2002-07-30 |
Genta Incorporated |
Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
AU2003237616B2
(en)
|
2002-01-17 |
2007-07-05 |
The University Of British Columbia |
Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
|
|
US20030147813A1
(en)
|
2002-02-07 |
2003-08-07 |
John Lyons |
Method for treating chronic myelogenous leukemia
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
EP2305812A3
(en)
*
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
CA2539651A1
(en)
*
|
2003-09-22 |
2005-04-07 |
Rosetta Inpharmatics Llc |
Synthetic lethal screen using rna interference
|
|
CA2563074C
(en)
*
|
2004-04-09 |
2014-05-20 |
Genomic Health, Inc. |
Gene expression markers for predicting response to chemotherapy
|
|
CA2620856C
(en)
|
2005-08-29 |
2017-11-28 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
US20080171718A1
(en)
|
2006-11-08 |
2008-07-17 |
Brown Bob D |
Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
|
|
JP5753382B2
(ja)
*
|
2007-11-06 |
2015-07-22 |
アディウティーダ ファーマシューティカルズ ゲーエムベーハー |
修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ
|
|
CA2736929C
(en)
|
2008-10-02 |
2019-02-26 |
Life Sciences Research Partners Vzw |
Inhibition of plgf to treat philadelphia chromosome positive leukemia
|
|
US9289505B2
(en)
|
2010-08-17 |
2016-03-22 |
Rutgers, The State University Of New Jersey |
Compositions and methods for delivering nucleic acid molecules and treating cancer
|
|
EP2675918B1
(en)
|
2011-02-15 |
2017-11-08 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
EP2683411B1
(en)
|
2011-03-09 |
2016-01-13 |
The Brigham and Women's Hospital, Inc. |
Methods of using microrna-26a to promote angiogenesis
|
|
JP5943993B2
(ja)
*
|
2011-04-01 |
2016-07-05 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節
|
|
EP3003275B1
(en)
|
2013-06-03 |
2020-11-18 |
Bar-Ilan University |
Liposomes for modulating wiskott-aldrich syndrome protein
|
|
JP6527516B2
(ja)
|
2013-12-03 |
2019-06-05 |
ノースウェスタン ユニバーシティ |
リポソーム粒子、前述のものを作製する方法及びその使用
|
|
WO2016164916A1
(en)
|
2015-04-10 |
2016-10-13 |
Thomas Jefferson University |
Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
|
|
CN108291227A
(zh)
|
2015-10-14 |
2018-07-17 |
拜奥-帕斯控股股份有限公司 |
用于脂质体制剂的对乙氧基核酸
|
|
AU2017325971A1
(en)
|
2016-09-16 |
2019-04-11 |
Bio-Path Holdings, Inc. |
Combination therapy with liposomal antisense oligonucleotides
|
|
US10357509B2
(en)
|
2017-03-09 |
2019-07-23 |
Thomas Jefferson University |
Methods and compositions for treating cancers using antisense
|
|
EA201992485A1
(ru)
|
2017-04-19 |
2020-02-17 |
Байо-Пат Холдингз, Инк. |
Р-этокси нуклеиновые кислоты для ингибирования stat3
|
|
AU2018255353B2
(en)
|
2017-04-19 |
2023-11-16 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for IGF-1R inhibition
|
|
EA201992490A1
(ru)
|
2017-04-19 |
2020-03-03 |
Байо-Пат Холдингз, Инк. |
Р-этокси нуклеиновые кислоты для ингибирования bcl2
|
|
CA3060090A1
(en)
|
2017-04-19 |
2018-10-25 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for igf-1r inhibition
|
|
MX2021011760A
(es)
|
2019-03-28 |
2021-12-10 |
Univ Jefferson |
Metodos para el tratamiento de canceres usando antisentido.
|
|
CN112830354A
(zh)
|
2019-11-22 |
2021-05-25 |
富泰华工业（深圳）有限公司 |
基于区块链系统的电梯调度系统、装置、方法及存储介质
|